Over the last decade, the field of oncology has undergone substantial changes in the way cancer patients are managed with an increasing focus on personalized medicine based on advances in tumor molecular profiling. Molecular profiling is a method that detects the presence of specific biomarkers, genes, proteins, or other molecules in tumor tissues or blood samples. Molecular profiling has significantly improved our understanding of the major molecular drivers in cancer, helps in the identification of types/subtypes of cancers, and aids in clinically relevant diagnostic and prognostic information and targeted treatment strategies. However, to date, these advances have not translated into better outcomes for the global cancer patient population.
Advances in molecular profiling have led to an improved understanding of the heterogeneity of cancers. The results obtained from the profiling have been used to inform diagnostic classification and targeted treatment strategies. In developed countries, targeted and personalized therapies are now commonplace in clinical practice. These therapies are tailored to the specific genetic or protein biomarkers that underlie and drive a patient’s tumor growth, metastasis, treatment resistance, and recurrence. However, a wide disparity exists globally in the availability of this testing technique.
Although not all populations have benefited equally from awareness of and access to testing, there is potential for incorporating tumor molecular profiling testing options into the standard of care for cancer patients worldwide. This will require a detailed understanding of the biomarkers detected at the various stages of cancer development to delineate cancer biology and to aid in the development of diagnostic tests and novel therapeutic strategies. Therefore, innovative research into the discovery and validation of novel cancer biomarkers is warranted to make clinically relevant treatment decisions for cancer patients worldwide.
The scope of the current Research Topic is to cover the recent advances in the discovery of cancer biomarkers for early diagnosis and treatment to tackle the rise in the incidence of cancer globally. We welcome original research articles, systematic review, meta-analysis, clinical case studies, and review articles within the scope of the research topic. Bioinformatics studies are welcome; however, these should not be based solely on analysis of publicly available datasets such as TCGA. Topic of interests includes, but are not limited to the following:
•Global Cancer
•Cancer biomarkers discovery
•Molecular mechanism involved in cancer initiation, progression, and metastasis
•Tumor molecular profiling methods
•Early diagnosis of cancer
•Novel therapeutic strategies
•Targeted therapies
Over the last decade, the field of oncology has undergone substantial changes in the way cancer patients are managed with an increasing focus on personalized medicine based on advances in tumor molecular profiling. Molecular profiling is a method that detects the presence of specific biomarkers, genes, proteins, or other molecules in tumor tissues or blood samples. Molecular profiling has significantly improved our understanding of the major molecular drivers in cancer, helps in the identification of types/subtypes of cancers, and aids in clinically relevant diagnostic and prognostic information and targeted treatment strategies. However, to date, these advances have not translated into better outcomes for the global cancer patient population.
Advances in molecular profiling have led to an improved understanding of the heterogeneity of cancers. The results obtained from the profiling have been used to inform diagnostic classification and targeted treatment strategies. In developed countries, targeted and personalized therapies are now commonplace in clinical practice. These therapies are tailored to the specific genetic or protein biomarkers that underlie and drive a patient’s tumor growth, metastasis, treatment resistance, and recurrence. However, a wide disparity exists globally in the availability of this testing technique.
Although not all populations have benefited equally from awareness of and access to testing, there is potential for incorporating tumor molecular profiling testing options into the standard of care for cancer patients worldwide. This will require a detailed understanding of the biomarkers detected at the various stages of cancer development to delineate cancer biology and to aid in the development of diagnostic tests and novel therapeutic strategies. Therefore, innovative research into the discovery and validation of novel cancer biomarkers is warranted to make clinically relevant treatment decisions for cancer patients worldwide.
The scope of the current Research Topic is to cover the recent advances in the discovery of cancer biomarkers for early diagnosis and treatment to tackle the rise in the incidence of cancer globally. We welcome original research articles, systematic review, meta-analysis, clinical case studies, and review articles within the scope of the research topic. Bioinformatics studies are welcome; however, these should not be based solely on analysis of publicly available datasets such as TCGA. Topic of interests includes, but are not limited to the following:
•Global Cancer
•Cancer biomarkers discovery
•Molecular mechanism involved in cancer initiation, progression, and metastasis
•Tumor molecular profiling methods
•Early diagnosis of cancer
•Novel therapeutic strategies
•Targeted therapies